ArticleFrontiers in medicine2025
Global, regional, and national burden of leukemia, 1990-2021: a systematic analysis of the global burden of disease in 2021.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Article
- Bacillus thuringiensis as a factory producing parasporin toxins with promising anticancer properties: a review.Microbial cell factories · 2026Review
- Transforming Hematology Care in Africa: Strategies for Enhanced Diagnosis and Treatment.Health science reports · 2026Article
- First-in-Class Dual PDGFR/Carbonic Anhydrase IX/XII Inhibitors: 6,7-Dimethoxyquinoline-Sulfonamides as Promising Antileukemic Agents.Journal of medicinal chemistry · 2026Article
- Burden of haematological malignancies among children, adolescents and young adults: Global and high-income region insights from the GBD 2021 study.British journal of haematology · 2026Article
- Long-term trends in the burden of leukemia subtypes in China from 1990 to 2021: a Joinpoint regression and age-period-cohort analysis based on GBD 2021.Frontiers in medicine · 2026Article
- Role of Gray Scattergram in Detecting Blasts Compared with Microscopic Peripheral Smear in Acute Leukemia Patients.Journal of blood medicine · 2026Article
- Leukemia disease burden and quality of care among adolescents and young adults in China compared to global patterns: a comprehensive analysis from 1990 to 2021.Frontiers in public health · 2026Article
- Leukemia Incidence and Demographic Trends in Saudi Arabia, 1997-2022: A Nationwide Registry Analysis.Journal of epidemiology and global health · 2025Article
- Global Burden of Chronic Lymphocytic Leukemia From 1990 to 2021.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leukemia is a heterogeneous hematologic malignancy with varying incidence, mortality, and disability-adjusted life years (DALYs) worldwide. Although the burden of leukemia has declined over recent decades, substantial disparities remain across different regions, socioeconomic levels, age groups, and sexes. This study looks at trends in leukemia cases, deaths, and the impact on quality of life from 1990 to 2021, aiming to uncover inequalities and help design better interventions. Methods: This study extracted data from the Global Burden of Disease (GBD) database (1990-2021) for five types of leukemia. The age-standardized incidence, mortality, and DALY rates for leukemia were calculated for 204 countries and 27 super regions worldwide. The estimated annual percentage change (EAPC) was used to quantify the trends in the leukemia burden, and trends were quantified using estimated annual percentage changes (EAPCs). Decomposition analysis examined the contributions of population growth, aging, and epidemiological changes. Additionally, autoregressive integrated moving average (ARIMA) and age-period-cohort (APC) models were employed. Inequality in leukemia burden was assessed using the Slope Index of Inequality (SII) and Concentration Index (CI). Results: Globally, the incidence and mortality of leukemia increased with age and were consistently higher in males. While incidence and mortality are projected to rise, DALYs are expected to decline slightly by 2031. Acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML) dominated incidence and mortality patterns, with higher ALL burdens in low-SDI regions and more pronounced AML burdens in higher-SDI regions. Decomposition analysis indicated that epidemiological changes and population growth drove trends in incidence and mortality, respectively. APC results showed declining period effects and lower risks in more recent birth cohorts. Inequality analyses revealed a growing disparity in incidence and mortality burdens in high-SDI countries, while DALYs inequality slightly narrowed. Conclusion: From 1990 to 2021, the global burden of leukemia has shifted, with persistent geographic, socioeconomic, and sex-related differences. Although overall improvements in prevention and treatment have reduced the DALYs burden, rising incidence and mortality in certain regions underscore the need for tailored public health strategies, early screening, and risk-based interventions to address persistent health inequalities and mitigate future leukemia burdens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.